Back to search results

MyMusiQ for Parkinson's Disease Walking Improvement

This study is testing a personalized walking program called MyMusiQ for people with Parkinson's disease (PD). MyMusiQ uses a special digital music device (MedRhythms, Inc.) with foot sensors, a smartphone app, and headphones to provide music cues while you walk. Researchers want to see if this personalized music can improve how well and how much you walk, make walking feel more automatic, and improve your overall quality of life. You might be able to join if you are at least 40 years old, have a Parkinson's diagnosis, live independently, and have stable PD medications. The study aims to measure changes in your moderate intensity walking over about three months. The current status of the study is unclear, and it plans to enroll 200 participants.

Study design
This is a single-arm study, meaning all participants will receive the intervention. It plans to enroll 200 participants.
What's involved
You would participate for about 18 weeks in total, with 4 study visits at designated research centers.
Compensation
Not stated in the trial record.
Follow-up
Your moderate intensity walking will be measured at baseline, again 2-3 weeks later, and immediately after the 3-month intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07705373

A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease

Recruiting
NAAges 40+InterventionalTreatment
Boston University Charles River Campus
~200 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:MR-005 (MedRhythms, Inc., Portland, ME)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Minutes of Moderate Intensity Walking
Measured over Baseline 1
+23 more outcomes measured

Conditions

Parkinson's Disease (PD)

Explore related trials

Parkinson Disease

NCT07705373

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Boston University Center for Neurorehabilitation

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • University of Utah

    Salt Lake City, Utahstudy coordinator listed

    Recruiting

  • Washington University School of Medicine

    St Louis, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Terry D. Ellis, PhD PT · PRINCIPAL_INVESTIGATOR · Boston University Center for Neurorehabilitation

Who to contact

Erica Clarke, BS
[email protected]
617-358-6157
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Self-report of diagnosis of typical Parkinson disease determined by a medical doctor
≥ 40 years of age
Community-dwelling (e.g. home, independent living, senior housing)
Have stable PD medications for at least two weeks prior to enrollment
Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist
Able to walk independently without physical assistance for at least 10 minutes (assistive devices allowed with reciprocal gait pattern)
Willing and able to provide informed consent
Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period

Exclusion

\< 40 years of age
Diagnosis of atypical Parkinsonism
Modified Hoehn and Yahr stages 4-5
Significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire (Part III Item 7)
Fall frequencies \>1x/week on average, over the past month.
Currently participating in physical therapy for Parkinson gait rehabilitation
Currently performing walking exercise at moderate intensities or higher for at least 30 min. per session ≥ 3x/week
Self-reported cardiac problems that interfere with the ability to safely exercise (e.g., congestive heart failure, uncontrolled cardiac arrhythmias, chest pain;
Orthopedic problems in the lower extremities or spine that may limit walking distance (e.g., severe arthritis, spinal stenosis, or significant pain)
Any other medical conditions that would preclude successful participation as determined by the researcher/ physical therapist
Cognitive impairment (i.e., Montreal Cognitive Assessment, MoCA \< 21)
Unable to walk independently (i.e., without physical assistance) at a comfortable speed ≥ 0.4m/s as measured using the 10-meter Walk Test (10mWT) as examined in Baseline #1
Resting tachycardia (\> 100 beats/min) or uncontrolled blood pressure (resting systolic BP \> 160 mmHg or diastolic BP \>100 mmHg)) as measured by the researcher/ physical therapist
Unable to independently use the music-based digital therapeutic during training
Significant hearing impairment

What this trial measures

  • Minutes of Moderate Intensity WalkingBaseline 1

    The amount of moderate intensity walking, defined as mean number of minutes per day with \>100 steps/min, measured using research-grade wearable sensors.

  • Minutes of Moderate Intensity WalkingBaseline 2 (2-3 weeks after Baseline 1)

    The amount of moderate intensity walking, defined as mean number of minutes per day with \>100 steps/min, measured using research-grade wearable sensors.

  • Minutes of Moderate Intensity WalkingImmediately after the intervention (about 3 months)

    The amount of moderate intensity walking, defined as mean number of minutes per day with \>100 steps/min, measured using research-grade wearable sensors.

  • Minutes of Moderate Intensity WalkingFollow-Up (about 1 month post-intervention)

    The amount of moderate intensity walking, defined as mean number of minutes per day with \>100 steps/min, measured using research-grade wearable sensors.

  • Daily Step CountsBaseline 1

    Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.

  • Daily Step CountsBaseline 2 (2-3 weeks after Baseline 1)

    Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.

  • Daily Step CountsImmediately after the intervention (about 3 months)

    Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.

  • Daily Step CountsFollow-Up (about 1 month post-intervention)

    Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.

  • 6-Minute Walk TestBaseline 1

    This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.

  • 6-Minute Walk TestBaseline 2 (2-3 weeks after Baseline 1)

    This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.

  • 6-Minute Walk TestImmediately after the intervention (about 3 months)

    This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.

  • 6-Minute Walk TestFollow-Up (about 1 month post-intervention)

    This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.

  • Gait SpeedBaseline 1

    Gait speed (m/s) will be measured using research-grade wearable sensors.

  • Gait SpeedBaseline 2 (2-3 weeks after Baseline 1)

    Gait speed (m/s) will be measured using research-grade wearable sensors.

  • Gait SpeedImmediately after the intervention (about 3 months)

    Gait speed (m/s) will be measured using research-grade wearable sensors.

  • Gait SpeedFollow-Up (about 1 month post-intervention)

    Gait speed (m/s) will be measured using research-grade wearable sensors.

  • Stride LengthBaseline 1

    Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.

  • Stride LengthBaseline 2 (2-3 weeks after Baseline 1)

    Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.

  • Stride LengthImmediately after the intervention (about 3 months)

    Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.

  • Stride LengthFollow-Up (about 1 month post-intervention)

    Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.

  • Variability of Stride TimeBaseline 1

    Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.

  • Variability of Stride TimeBaseline 2 (2-3 weeks after Baseline 1)

    Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.

  • Variability of Stride TimeImmediately after the intervention (about 3 months)

    Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.

  • Variability of Stride TimeFollow-Up (about 1 month post-intervention)

    Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.